Predictive factors of prognosis after radiation and steroid pulse therapy in thyroid eye disease.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 02 2019
Historique:
received: 04 10 2018
accepted: 04 01 2019
entrez: 16 2 2019
pubmed: 16 2 2019
medline: 9 9 2020
Statut: epublish

Résumé

To identify predictive factors of prognosis after radiotherapy with concurrent steroid pulse therapy for thyroid eye disease, retrospective analyses were performed among 77 patients. Clinical activity score and magnetic resonance imaging were used to evaluate degrees of orbital inflammation. As a pre-treatment work-up, the thyroid-stimulating antibody (TSAb) level was measured. During a median follow-up of 25.0 months, the 2-year cumulative relapse-free rate (CRFR) was 80.9%. In the univariate analysis, a worse 2-year CRFR was significantly associated with the presence of optic neuropathy (P = 0.001), a higher TSAb rate (P = 0.001), and lower standard deviation (SD) of signal intensity at the extraocular muscle in T2-weighted images (P = 0.006). In the multivariate analysis, TSAb rate and SD affected the CRFR independently. When TSAb activity of 2800% was set as a cut-off at 2 years after treatment, the predictive sensitivity and specificity of relapse were 81.2% and 90.6%, respectively. With regard to SD, the respective sensitivity and specificity values were 81.2% and 82.7% when 100 was set as a cut-off. In conclusion, high TSAb and low SD were significant risk factors for cumulative relapse in orbital radiotherapy. Cut-off values of 2800% for TSAb and 100 for SD may be suitable.

Identifiants

pubmed: 30765815
doi: 10.1038/s41598-019-38640-5
pii: 10.1038/s41598-019-38640-5
pmc: PMC6376132
doi:

Substances chimiques

Steroids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2027

Références

Semin Radiat Oncol. 1999 Apr;9(2):179-89
pubmed: 10092710
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):857-64
pubmed: 11020584
Thyroid. 2000 Sep;10(9):809-13
pubmed: 11041459
Thyroid. 2002 Mar;12(3):223-7
pubmed: 11952043
Thyroid. 1992 Winter;2(4):299-305
pubmed: 1493371
J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40
pubmed: 15998777
Acta Paediatr. 2007 May;96(5):644-7
pubmed: 17376185
Medicina (Kaunas). 2007;43(3):190-8
pubmed: 17413247
N Engl J Med. 2009 Mar 5;360(10):994-1001
pubmed: 19264688
Clin Endocrinol (Oxf). 2010 Aug;73(2):149-52
pubmed: 20148907
Endocr J. 2010;57(10):853-61
pubmed: 20733265
Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):259-64
pubmed: 2118493
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1285-91
pubmed: 21550180
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Arq Bras Oftalmol. 2012 Oct;75(5):324-32
pubmed: 23471326
Thyroid. 2015 Oct;25(10):1145-50
pubmed: 26213859
Br J Ophthalmol. 1989 Aug;73(8):639-44
pubmed: 2765444
N Engl J Med. 2016 Oct 20;375(16):1552-1565
pubmed: 27797318

Auteurs

Makoto Ito (M)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan. itou.makoto.292@mail.aichi-med-u.ac.jp.

Yasuhiro Takahashi (Y)

Department of Oculoplastic, Orbital, and Lacrimal Surgery, Aichi Medical University Hospital, Aichi, Japan.

Eisuke Katsuda (E)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Yukihiko Oshima (Y)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Arisa Takeuchi (A)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Toshie Mori (T)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Souichirou Abe (S)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Yoshimasa Mori (Y)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Hirohiko Kakizaki (H)

Department of Oculoplastic, Orbital, and Lacrimal Surgery, Aichi Medical University Hospital, Aichi, Japan.

Kojiro Suzuki (K)

Department of Radiology, Aichi Medical University Hospital, Aichi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH